<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Palliative care: Overview of cough, stridor, and hemoptysis in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Palliative care: Overview of cough, stridor, and hemoptysis in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Palliative care: Overview of cough, stridor, and hemoptysis in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles von Gunten, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gary Buckholz, MD, FAAHPM</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eduardo Bruera, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jane Givens, MD, MSCE</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 16, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2990402"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The symptoms of cough, stridor, and hemoptysis are common in palliative care patients with advanced life-threatening illness, especially cancer. These respiratory symptoms may be frightening to patients, families, and caregivers. (See  <a class="medical medical_review" href="/d/html/14238.html" rel="external">"Assessment and management of dyspnea in palliative care"</a>.)</p><p>Palliative management focuses on symptom relief; this may occur alongside therapies to treat or reverse the underlying cause(s). Palliative management also includes the amelioration of the psychosocial and spiritual impacts of these potentially life-threatening symptoms, utilizing a team approach. (See  <a class="medical medical_review" href="/d/html/86307.html" rel="external">"Palliative care for adults with nonmalignant chronic lung disease"</a>.)</p><p class="headingAnchor" id="H2990409"><span class="h1">COUGH</span><span class="headingEndMark"> — </span>This section will summarize palliative management of cough in the setting of an advanced life-threatening illness. A more general approach to acute and chronic cough in adults is discussed separately. (See  <a class="medical medical_review" href="/d/html/1460.html" rel="external">"Causes and epidemiology of subacute and chronic cough in adults"</a> and  <a class="medical medical_review" href="/d/html/1428.html" rel="external">"Evaluation and treatment of subacute and chronic cough in adults"</a>.)</p><p>Cough is a mechanism to clear the airways of mucus and foreign bodies when mucociliary transport is insufficient. When a cough becomes chronic, it can be disruptive, distressing, and physically exhausting. It may impair social relationships and worsen other symptoms such as pain, dyspnea, incontinence, and sleep disturbance [<a href="#rid1">1</a>] or cause rib fractures [<a href="#rid2">2</a>]. The mildest cough may be almost imperceptible to the patient, yet its importance to the patient and family or other loved ones is linked to the underlying disease (eg, the cancer is still there). The most severe cough is convulsive, unending, and permits no other object of attention.</p><p class="headingAnchor" id="H4218297962"><span class="h2">Initial evaluation</span></p><p class="bulletIndent1"><span class="glyph">●</span>A history should be obtained in all patients. Useful historical features include duration (acute, subacute, or chronic) of cough, type of cough (productive/nonproductive), trigger factors, nocturnal versus daytime pattern, severity, impact on quality of life, and past medical history (history or asthma, chronic obstructive pulmonary disease [COPD], interstitial lung disease, heart failure). This can help identify the cause of cough and determine whether therapy is needed.</p><p></p><p class="bulletIndent1">The initial evaluation for common causes of cough in general is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/1460.html" rel="external">"Causes and epidemiology of subacute and chronic cough in adults", section on 'Causes of chronic cough'</a>.)</p><p></p><p class="bulletIndent1">Many common causes of cough among palliative care populations are similar to those in the general population and can be categorized by duration  (<a class="graphic graphic_table graphicRef91823" href="/d/graphic/91823.html" rel="external">table 1</a>). Pulmonary toxicity from chemotherapy drugs is a special consideration among palliative care patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The need for chest radiograph or other diagnostic interventions depends on the individualized goals of care and likelihood of pursuing treatment based on the test result. On the other hand, when imaging or other diagnostic tests are easy to perform and/or low burden to the patient, they should not be disregarded when the goals are comfort-oriented. For example, if a chest radiograph would help determine whether antibiotics should be utilized to treat an infection in a hospitalized patient, this low-burden intervention would provide information to guide a symptomatic benefit even if the goals are comfort-oriented. Often, extensive evaluation is not needed and should not delay appropriate symptomatic therapy. (See <a class="local">'Symptom-directed treatment'</a> below.)</p><p></p><p class="headingAnchor" id="H1844665605"><span class="h2">Treatment of underlying causes</span></p><p class="headingAnchor" id="H1892381064"><span class="h3">Common general causes</span><span class="headingEndMark"> — </span>Cough in palliative care patients can be due to causes similar to those in the general population. In some patients, the cough is an indication that there is an exacerbation of a comorbid illness (such as COPD or bronchiectasis) or an acute pulmonary infection that can be treated. Cough may also be due to conditions which can be relatively easily addressed, such as gastroesophageal reflux disease (GERD), or caused by a medication side effect (eg, angiotensin-converting enzyme [ACE] inhibitors). While cessation of cigarette smoking (or other inhaled irritants) is useful as a response to resultant cough in the general population, smoking cessation is often not realistic and/or helpful in patients with a limited prognosis of weeks or a short number of months.</p><p>Management of such causes of cough are similar to the general population and are discussed in further detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7031.html" rel="external">"Treatment of community-acquired pneumonia in adults in the outpatient setting"</a> and  <a class="medical medical_review" href="/d/html/1461.html" rel="external">"COPD exacerbations: Management"</a> and  <a class="medical medical_review" href="/d/html/1428.html" rel="external">"Evaluation and treatment of subacute and chronic cough in adults", section on 'Empiric therapy for common causes'</a>.)</p><p class="headingAnchor" id="H3780733996"><span class="h3">Specific causes in palliative care</span><span class="headingEndMark"> — </span>Certain causes of cough are more common in palliative care patients.</p><p class="headingAnchor" id="H4197483760"><span class="h4">Ineffective swallowing</span><span class="headingEndMark"> — </span>In palliative care populations, the cough reflex is often stimulated by attempts to clear accumulating secretions due to asthenia, muscle weakness, and the inability to coordinate an effective swallow [<a href="#rid3">3</a>]. Typical patient signs may include drooling and cough brought on by eating and/or drinking. Common causes of swallowing disorders in palliative care are described elsewhere. (See  <a class="medical medical_review" href="/d/html/85949.html" rel="external">"Swallowing disorders and aspiration in palliative care: Definition, pathophysiology, etiology, and consequences", section on 'Etiology of swallowing disorders in palliative care populations'</a>.)</p><p>A bedside swallowing evaluation may be helpful. This will consist of a detailed history and examination by a speech therapist along with observance of swallowing a series of substances. The therapist will note if there are problems chewing, swallowing, or breathing. If the swallow evaluation is abnormal, a <a class="drug drug_general" data-topicid="9180" href="/d/drug information/9180.html" rel="external">barium</a> swallowing study can assist with identifying aspiration. Interventions depend on the patient’s goals of care and include specific swallowing strategies, dietary modifications, and pharmacologic agents. (See  <a class="medical medical_review" href="/d/html/95508.html" rel="external">"Swallowing disorders and aspiration in palliative care: Assessment and strategies for management"</a>.)</p><p class="headingAnchor" id="H105887382"><span class="h4">Malignant disease</span><span class="headingEndMark"> — </span>Malignancies likely to cause cough include those of the airways, lungs, pleura, and mediastinum, or cancers that metastasize to the thorax [<a href="#rid4">4,5</a>]. Cough is present in up to 90 percent of patients with advanced lung or head and neck cancer [<a href="#rid6">6-8</a>]. The direct and indirect causes of cough associated with advanced cancer are listed in the table  (<a class="graphic graphic_table graphicRef91822" href="/d/graphic/91822.html" rel="external">table 2</a>).</p><p>Palliative treatment options for endobronchial tumors include chemotherapy, radiotherapy, endobronchial laser resection, or stent placement. As a general rule, cough improves if directed therapy reduces the impact of the cancer. However, symptom improvement with palliative chemotherapy, radiotherapy, or endobronchial brachytherapy may take several weeks [<a href="#rid9">9-11</a>]. (See  <a class="medical medical_review" href="/d/html/4384.html" rel="external">"Clinical presentation, diagnostic evaluation, and management of malignant central airway obstruction in adults", section on 'Diagnostic evaluation and initial management'</a>.)</p><p class="headingAnchor" id="H1850214366"><span class="h4">Chronic infections</span><span class="headingEndMark"> — </span>In palliative care patients with cystic fibrosis or other chronic lung disease, chronic infections may contribute to cough symptoms. In such cases, antibiotics may be useful for palliative suppression of cough [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection"</a> and  <a class="medical medical_review" href="/d/html/7019.html" rel="external">"Management of infection in exacerbations of chronic obstructive pulmonary disease", section on 'Prophylactic macrolides'</a>.)</p><p class="headingAnchor" id="H457216356"><span class="h2">Symptom-directed treatment</span><span class="headingEndMark"> — </span>The mainstay of symptom-directed pharmacologic therapy is cough suppression with antitussives, which can be used alone or alongside disease-specific treatments. Our approach to treatment is described in the algorithm  (<a class="graphic graphic_algorithm graphicRef131668" href="/d/graphic/131668.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H2440863821"><span class="h3">Mild cough</span><span class="headingEndMark"> — </span>For patients with mild cough, we suggest a trial of nonpharmacologic therapies as a first step. Options include use of a linctus such as honey, breathing exercises, cough suppression techniques, and patient counseling [<a href="#rid13">13-19</a>]. If these are ineffective, we then suggest a peripherally acting antitussive (eg, <a class="drug drug_general" data-topicid="9098" href="/d/drug information/9098.html" rel="external">benzonatate</a>). If symptoms do not improve with a peripherally acting antitussive, we suggest treatment with a centrally acting antitussive, as for patients with more severe cough. (See <a class="local">'Moderate to severe cough'</a> below.)</p><p><a class="drug drug_general" data-topicid="9098" href="/d/drug information/9098.html" rel="external">Benzonatate</a> presumably anesthetizes stretch receptors in the lungs and pleura. The recommended dose is 100 to 200 mg three times daily. Data supporting the use of benzonatate are limited, but it is a reasonable first option. Anecdotal evidence suggested benefit in patients with advanced cancer and opioid-resistant cough [<a href="#rid20">20</a>]. However, earlier studies had not shown benefit over placebo in patients with bronchitis or COPD [<a href="#rid20">20,21</a>].</p><p>Other peripherally acting antitussives that are available in certain countries include levodropropizine [<a href="#rid22">22,23</a>], moguisteine [<a href="#rid24">24</a>], and levocloperastine [<a href="#rid25">25</a>].</p><p>Utilization of a fan is helpful for dyspnea but has scant evidence for palliation of cough, although there is low risk as long as there is no concern for airborne infectious pathogens [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H1918284437"><span class="h3">Moderate to severe cough</span><span class="headingEndMark"> — </span>Centrally active agents are appropriate for patients with moderate to severe cough, including cough that impairs sleep and cough that does not respond to peripherally acting agents. We suggest opioids as first-line treatment, or, if opioids are contraindicated, <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> or <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">pregabalin</a>.</p><p>Nebulized local anesthetics, such as <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> or <a class="drug drug_general" data-topicid="9169" href="/d/drug information/9169.html" rel="external">bupivacaine</a>, have been proposed for the most serious cases but may be associated with bronchospasm [<a href="#rid27">27,28</a>]. These agents are most likely to be used in specialized palliative care units.</p><p>We do not use <a class="drug drug_general" data-topicid="8893" href="/d/drug information/8893.html" rel="external">dextromethorphan</a> (an antitussive antagonist of the N-methyl-D-aspartate receptor and the major ingredient in most over-the-counter cough syrups) for treatment of chronic cough, due to limited evidence of efficacy [<a href="#rid29">29-31</a>]. Although dextromethorphan is frequently used in the general population, in which cough is often of limited duration, we favor using more effective agents upfront in the palliative care population.</p><p class="headingAnchor" id="H1534149848"><span class="h4">Opioids</span><span class="headingEndMark"> — </span>Opioids are a mainstay of pharmacologic therapy for palliative care patients with moderate to severe chronic cough, particularly those with intrathoracic cancer. Some clinicians are hesitant to use them due to concern of opioid misuse or addiction; however, such concerns in a palliative care population are rare.</p><p>Appropriate options for cough suppression in opioid-naïve patients include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">Morphine</a> 5 mg by mouth every four hours as needed for moderate to severe cough. If benefits from routine use of immediate release opioids are demonstrated, long-acting preparations can be considered for constant cough. Similar equianalgesic dosing of 1 to 2 mg intravenously (IV) or subcutaneously can be utilized if the patient is unable to take oral medications or for ease of administration especially in the hospital setting.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A different opioid at equianalgesic dosing to <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> 5 mg by mouth also can be utilized.</p><p></p><p>For patients already receiving opioids for pain, a 25 to 50 percent dose increase may be tried to suppress the cough.</p><p><a class="drug drug_general" data-topicid="9291" href="/d/drug information/9291.html" rel="external">Codeine</a> 15 mg orally every four hours as needed is an appropriate dose for cough suppression. However, codeine is metabolized to <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> by a cytochrome P450 enzyme, and patients who have variants of this enzyme, including many Asian patients, are at risk of experiencing adverse effects of codeine without the benefit [<a href="#rid32">32</a>]. We therefore use morphine preferentially.</p><p class="bulletIndent1">Data suggest that opioids improve cough in palliative care populations, although the evidence in this population is limited. In a 2013 meta-analysis of trials evaluating various treatments for chronic cough, which included only a few trials with cancer patients, opioids reduced cough severity (standardized mean difference 0.55, 95% CI 0.38-0.72) and cough frequency (rate ratio 0.57, 95% CI 0.36-0.91) compared with placebo [<a href="#rid33">33</a>]. They also improved quality of life. No opioid was superior to another.</p><p></p><p>A 2015 systematic review of trials examining interventions for cough in patients with primary or metastatic cancer also noted some positive effect with opioids (<a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a>, <a class="drug drug_general" data-topicid="9291" href="/d/drug information/9291.html" rel="external">codeine</a>, and dihydrocodeine), although there was significant risk of bias in all trials [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H3190395009"><span class="h4">Gabapentin and pregabalin</span><span class="headingEndMark"> — </span>Alternative or concurrent treatments for chronic cough are the gamma aminobutyric acid (GABA) analogs <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> and <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">pregabalin</a>. We recommend these agents for patients with moderate to severe cough who are unable to take opioids.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">Gabapentin</a> is initiated at a low dose (300 mg/day) with gradual increases until cough relief, dose-limiting adverse effects, or a dose of 900 mg twice daily is achieved [<a href="#rid35">35</a>]. Patients should be monitored for sedation, which typically wanes one to three days after each dose escalation. Additional adverse effects may include dizziness, diarrhea, nausea, emotional lability, somnolence, nystagmus, tremor, weakness, and peripheral edema. While additional data are needed, studies have shown gabapentin is helpful and safe when compared with placebo for chronic cough [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">Pregabalin</a> is initiated at a low dose (eg, 75 mg/day) and gradually increased over a week to 300 mg/day to minimize sedation and dizziness.</p><p></p><p>While <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> may help with treatment of chronic cough, it may also have a more specific role in treating refractory gastroesophageal reflux-induced cough [<a href="#rid37">37</a>].</p><p>Support for the use of <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> and <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">pregabalin</a> for alleviation of chronic cough in palliative care populations is based on evidence in the general population, which is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1428.html" rel="external">"Evaluation and treatment of subacute and chronic cough in adults", section on 'Gabapentin and pregabalin'</a>.)</p><p class="headingAnchor" id="H1204601023"><span class="h4">Rare use of combination therapy</span><span class="headingEndMark"> — </span>Concomitant use of opioids and GABA analogs can be attempted if there is concern that a component of the cough may be due to nerve irritation and thus not completely managed with opioids alone. However, this combination of agents must be approached with caution due to the possibility of significant adverse side effects of increased sedation and risk of opioid-related death [<a href="#rid38">38</a>].</p><p>We recommend starting these agents sequentially, as there can be significant sedation when starting <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> even at low doses. Gabapentin initiation merits its own escalation strategy. (See <a class="local">'Opioids'</a> above and <a class="local">'Gabapentin and pregabalin'</a> above.)</p><p class="headingAnchor" id="H1357767234"><span class="h3">Adjunctive therapies</span><span class="headingEndMark"> — </span>For patients who do not have an adequate response to therapy, we consider adding one or more adjunctive treatments based on additional symptoms, although some of these therapies have uncertain benefit:</p><p class="bulletIndent1"><span class="glyph">●</span>Thick sputum – Add expectorant (eg <a class="drug drug_general" data-topicid="8503" href="/d/drug information/8503.html" rel="external">guaifenesin</a>, nebulized <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>) or mucolytic (eg, <a class="drug drug_general" data-topicid="9317" href="/d/drug information/9317.html" rel="external">acetylcysteine</a>) (see <a class="local">'Pharmacologic therapies of uncertain benefit'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Bronchospasm – Add bronchodilator (eg, inhaled albuterol-ipratropium)</p><p class="bulletIndent1"><span class="glyph">●</span>Excess secretions – Add anticholinergic (eg, <a class="drug drug_general" data-topicid="8496" href="/d/drug information/8496.html" rel="external">glycopyrrolate</a>)</p><p></p><p class="headingAnchor" id="H739530847"><span class="h3">The dying patient</span><span class="headingEndMark"> — </span>In the last hours and days of life, cough can affect up to 80 percent of patients; contributory factors are asthenia, muscle weakness, and increased respiratory secretions. In addition to other symptomatic therapies, anticholinergic drugs, such as <a class="drug drug_general" data-topicid="8496" href="/d/drug information/8496.html" rel="external">glycopyrrolate</a> IV, subcutaneously, or sublingually, can be given to minimize bronchial secretions and thus improve cough [<a href="#rid39">39-41</a>]. (See  <a class="medical medical_review" href="/d/html/14241.html" rel="external">"Palliative care: The last hours and days of life", section on 'Airway secretions'</a>.)</p><p class="headingAnchor" id="H105887762"><span class="h3">Pharmacologic therapies of uncertain benefit</span><span class="headingEndMark"> — </span>Other pharmacologic strategies have been used with limited success for certain symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Expectorants and mucolytics for thick secretions</strong> – Thick secretions are common in palliative care patients with cough, and expectorants (eg, <a class="drug drug_general" data-topicid="8503" href="/d/drug information/8503.html" rel="external">guaifenesin</a>, nebulized <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>) or mucolytics (eg, <a class="drug drug_general" data-topicid="9317" href="/d/drug information/9317.html" rel="external">acetylcysteine</a>) may be used to reduce the viscosity of secretions. However, these agents, which are referred to as “protussives,” are not cough suppressants, and they do not reduce the frequency or severity of cough. As an example, a systematic review of therapies for chronic cough found only limited data describing benefit of guaifenesin in reducing cough intensity and no benefit from mucolytics [<a href="#rid33">33,42</a>]. Additionally, patients who are dehydrated may need additional fluid ingestion if treated with expectorants, and these agents should not be used in patients with neuromuscular diseases such as amyotrophic lateral sclerosis, many of whom will not be able to cough out the liquified mucus [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurokinin (NK)-1 receptor inhibition</strong> – Activation of NK-1 receptors by substance P may contribute to chronic cough, and treatments that block this pathway have been studied as antitussives with variable results [<a href="#rid44">44,45</a>]. <a class="drug drug_general" data-topicid="9305" href="/d/drug information/9305.html" rel="external">Aprepitant</a> is an NK-1 receptor inhibitor traditionally used for treatment of chemotherapy-related nausea and vomiting. In a randomized crossover trial of 20 patients (mean age 66 years) with lung cancer and bothersome cough, patients who received three days of aprepitant had greater cough reduction while awake (22.2 percent) and while asleep (59.8 percent) compared with those who received placebo [<a href="#rid46">46</a>]. It is not known whether a higher dose of aprepitant would have had greater efficacy. Additional research is needed with a larger study population, longer duration, and optimized dosing; cost considerations may limit use. (See  <a class="medical medical_review" href="/d/html/2538.html" rel="external">"Characteristics of antiemetic drugs", section on 'Neurokinin receptor antagonists'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">Paroxetine</a> – There is a small amount of evidence that paroxetine may have a role in treating cough in cancer patients [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">Thalidomide</a> <strong>for idiopathic pulmonary fibrosis</strong> – Thalidomide may have a role in treating cough in patients with idiopathic pulmonary fibrosis [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiseizure agents for intractable, centrally mediated cough </strong>– While rare, intractable, centrally mediated cough may require benzodiazepines with antiseizure and sedative properties to assist with management especially near the end of life. [<a href="#rid49">49</a>]. There are reports of <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a> and <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> being helpful in select patients [<a href="#rid50">50,51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9062" href="/d/drug information/9062.html" rel="external">Baclofen</a> – Baclofen, likely mediated through a central mechanism, may be helpful in cough since it was effective in a small trial treating capsaicin-induced cough [<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">Amitriptyline</a> – In small trials Amitriptyline has been shown to be effective for chronic sensory neuropathic cough [<a href="#rid53">53</a>] and cough associated with postviral vagal neuropathy [<a href="#rid54">54</a>].</p><p></p><p class="headingAnchor" id="H2990430"><span class="h1">STRIDOR</span><span class="headingEndMark"> — </span>Stridor is a harsh, high-pitched wheezing or vibrating sound that results from turbulent airflow in the upper airways. It most typically occurs with inspiration but can also occur during expiration.</p><p class="headingAnchor" id="H2990437"><span class="h2">Pathogenesis and underlying causes</span><span class="headingEndMark"> — </span>Generally, stridor results from a narrowing of a central airway or the larynx caused by a foreign body, a tumor pushing extrinsically or growing intrinsically, infection, or edema. Information on the diagnostic evaluation of stridor is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/4384.html" rel="external">"Clinical presentation, diagnostic evaluation, and management of malignant central airway obstruction in adults"</a>.)</p><p>For patients with cancer, stridor can occur with squamous cell carcinomas of the larynx, trachea, or esophagus. In addition, superior sulcus tumors of the right upper lobe (the so-called “Pancoast” tumors) can extrinsically compress the superior vena cava (SVC), leading to SVC syndrome. In this setting, secondary interstitial edema of the head and neck may narrow the lumen of the nasal passages and larynx, resulting in dyspnea, stridor, cough, hoarseness, and dysphagia. (See  <a class="medical medical_review" href="/d/html/4605.html" rel="external">"Superior pulmonary sulcus (Pancoast) tumors"</a> and  <a class="medical medical_review" href="/d/html/2832.html" rel="external">"Malignancy-related superior vena cava syndrome"</a>.)</p><p>Rapid obstruction or narrowing can precipitate a palliative care emergency, associated with significant anxiety for patients, families, and health care professionals.</p><p class="headingAnchor" id="H474363999"><span class="h2">Management</span><span class="headingEndMark"> — </span>Patients who present with stridor due to severe tracheal or mainstem bronchial obstruction or severe laryngeal edema and respiratory compromise represent a true medical emergency. They are at high risk for respiratory failure and death, and they require initial stabilization to secure ventilation and oxygenation, if this is consistent with the goals of care.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Emergency intervention to stabilize the airway</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>When stridor is of sudden onset, administration of racemic <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> for a potentially allergic cause of anaphylaxis may be used in a therapeutic trial before opioids and benzodiazepines are initiated. (See  <a class="medical medical_review" href="/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Endotracheal intubation is preferred.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In cases of severe tracheal obstruction, use of the open ventilating rigid bronchoscope is the preferred method of airway control. (See  <a class="medical medical_review" href="/d/html/4391.html" rel="external">"Rigid bronchoscopy: Intubation techniques"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Occasionally, emergency tracheostomy is needed for palliation of upper airway tumors so the patient does not suffocate.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>While somewhat controversial, the use of continuous positive pressure ventilation has been studied in head and neck cancer patients [<a href="#rid55">55</a>] and multiple system atrophy [<a href="#rid56">56</a>] for palliative management of stridor. If possible, care should be taken to assess potential for airway management to suddenly become more urgent, risk for skin issues related to excessive mask pressure, and risk of bleeding with high inspiratory pressure and mask-related pressure [<a href="#rid57">57</a>].</p><p></p><p class="bulletIndent1">The initial management of central airway obstruction is presented in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/4384.html" rel="external">"Clinical presentation, diagnostic evaluation, and management of malignant central airway obstruction in adults", section on 'Diagnostic evaluation and initial management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of dyspnea and anxiety</strong> – In all cases, management of the experience of the patient and those who are watching is important. When the underlying cause cannot be reversed, it is paramount that symptomatic control be swift and confident. Dyspnea and anxiety should be managed with opioids and benzodiazepines (see  <a class="medical medical_review" href="/d/html/14238.html" rel="external">"Assessment and management of dyspnea in palliative care", section on 'Opioids'</a> and  <a class="medical medical_review" href="/d/html/4853.html" rel="external">"Management of psychiatric disorders in patients with cancer", section on 'Pharmacotherapy'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In an opioid-naïve patient, 5 to 10 mg <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> may be administered intravenously (IV), or subcutaneously if there is no IV access. The dose may be repeated every 10 minutes (time to maximum serum concentration) IV or every 30 minutes subcutaneously in order to titrate to comfort. The dose may also be doubled with each subsequent dose until the patient reports relief. Once comfort is achieved, a total dose can be calculated and administered every half-life for steady-state maintenance or given as a continuous infusion. Sometimes the maintenance dose is less than that needed to achieve initial comfort because anxiety is reduced; you will have demonstrated to the patient and family that you can control the symptom.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If anxiety is prominent, a benzodiazepine such as <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a> may be added at a dose of 0.5 to 1 mg IV every 15 minutes or subcutaneously every hour to titrate to comfort. For highly symptomatic patients, sedation may be required to relieve distress to the satisfaction of the patient and family or other loved ones. (See  <a class="medical medical_review" href="/d/html/83710.html" rel="external">"Palliative sedation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Palliation of central airway obstruction</strong> – Once initial control of the symptom is achieved, attention to the underlying cause can be entertained. A diagnostic evaluation may lead to more definitive therapy, if doing so is consistent with the goals of care. In one study, urgent therapeutic bronchoscopy allowed 52 percent of patients with malignant central airway obstruction to come off of the ventilator [<a href="#rid58">58</a>]. For selected patients with a central airway obstruction, single-fraction radiotherapy, endoscopic stent placement, endobronchial laser ablation, or argon plasma coagulation may have a role if treatment of the underlying cause is consistent with the goals of care. For patients with SVC syndrome, endovascular stenting or thrombolytic therapy are also options. (See  <a class="medical medical_review" href="/d/html/2832.html" rel="external">"Malignancy-related superior vena cava syndrome", section on 'Treatment'</a> and  <a class="medical medical_review" href="/d/html/4384.html" rel="external">"Clinical presentation, diagnostic evaluation, and management of malignant central airway obstruction in adults", section on 'Diagnostic evaluation and initial management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Establishing patient preferences regarding alertness vs sedation</strong> – Standard approaches to discussing the benefits and burdens of treatment require special modification in the setting of a palliative care emergency such as severe stridor. A question such as “How would you like me to manage your stridor?” is not a helpful approach in the heat of the moment. Rather, an opening statement such as the following is more appropriate: “We are going to make every attempt to bring your symptoms under control. Sometimes, there is a tension between providing enough to keep you comfortable but not so much as to make you sleepy. If we have to err on one side or the other, on which side should we err: alertness or comfort?”</p><p></p><p class="headingAnchor" id="H2990451"><span class="h1">HEMOPTYSIS</span><span class="headingEndMark"> — </span>Hemoptysis is blood coughed up from a pulmonary source. Hemoptysis must be differentiated from pseudohemoptysis (expectoration of blood originating in the nasopharynx or oropharynx) and hematemesis (vomiting of blood). Pseudohemoptysis can be diagnosed by inspection of the nasopharynx and oropharynx, and hematemesis by other gastrointestinal symptoms and risk factors for gastrointestinal tract bleeding. Characteristics of the expectorated material that suggest that a gastrointestinal source is <strong>unlikely</strong> include an alkaline pH, foaminess, and/or the presence of pus. Information on the diagnostic evaluation of hemoptysis is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/4333.html" rel="external">"Evaluation of nonlife-threatening hemoptysis in adults"</a>.)</p><p>Life-threatening hemoptysis is generally used to describe the expectoration of a large amount of blood and/or a rapid rate of bleeding, although the precise thresholds that constitute life-threatening hemoptysis are controversial. Some define life-threatening hemoptysis as ≥150 mL of expectorated blood over a 24-hour period or bleeding at a rate ≥100 mL/hour. (See  <a class="medical medical_review" href="/d/html/4394.html" rel="external">"Evaluation and management of life-threatening hemoptysis", section on 'Definition'</a>.)</p><p class="headingAnchor" id="H2990458"><span class="h2">Pathogenesis and underlying causes</span><span class="headingEndMark"> — </span>In palliative care populations, hemoptysis often arises from high-pressure bronchial circulation but can occur in patients via erosion of tumor or when low-pressure pulmonary capillaries are affected by inflammation. This can occur with primary or secondary lung cancer, terminal hematological malignancy, lung infection or abscess, bronchiectasis, pulmonary embolism, cystic fibrosis [<a href="#rid59">59</a>], bleeding disorders, anticoagulant use, anti-GBM (Goodpasture) disease, granulomatosis with polyangiitis, and other less common conditions  (<a class="graphic graphic_table graphicRef91871" href="/d/graphic/91871.html" rel="external">table 3</a>) (see  <a class="medical medical_review" href="/d/html/4333.html" rel="external">"Evaluation of nonlife-threatening hemoptysis in adults"</a>). Among patients with cancer, hemoptysis is most common in lung cancer. It is the presenting symptom in 7 to 10 percent of lung cancer patients, and approximately 20 percent will have hemoptysis during the course of their illness [<a href="#rid60">60</a>].</p><p>Pulmonary hemorrhage is also a known complication of the antiangiogenic agent <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>, especially in patients with squamous cell bronchogenic carcinoma. The use of bevacizumab is contraindicated in patients with squamous cell lung carcinoma and in any patient with hemoptysis (&gt;2.5 mL of blood) within three months. (See  <a class="medical medical_review" href="/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Pulmonary hemorrhage and cavitation'</a>.)</p><p>Although hemoptysis is common in bronchogenic carcinoma, life-threatening terminal hemoptysis (eg, from erosion of the tumor into a blood vessel) is rare, occurring in only 3 percent of 877 patients in one series [<a href="#rid61">61</a>]. When it does occur, life-threatening hemoptysis associated with bronchogenic carcinoma has an extremely grim prognosis (mortality 59 to 100 percent), making it a palliative care emergency. Other causes of life-threatening hemoptysis are bronchiectasis, pulmonary tuberculosis, and fungal pulmonary infection. (See  <a class="medical medical_review" href="/d/html/15663.html" rel="external">"Etiology of hemoptysis in adults", section on 'Causes of life-threatening hemoptysis'</a>.)</p><p class="headingAnchor" id="H2990465"><span class="h2">Management</span><span class="headingEndMark"> — </span>Treatment should be tailored to the patient’s overall status, the severity of hemoptysis, the underlying cause, and the wishes of the patient and family or other loved ones. The patient and family/loved ones can often be best supported by the provision of goal-directed information and recommendations for management. It may be necessary to share prognostic information quickly to help determine the best goals of care and, subsequently, the best medical decisions. Using a team approach, psychosocial and spiritual needs can be addressed just as quickly as the physical symptoms. (See  <a class="medical medical_review" href="/d/html/4394.html" rel="external">"Evaluation and management of life-threatening hemoptysis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Minimizing patient and family distress</strong> – The palliative treatment of hemoptysis is primarily related to managing the experience of the patient, family, and other loved ones, as well as efforts to stop the bleeding if this is consistent with the overall goals of care. At a minimum, reassurance when the amount of blood is small is all that is required. Dark towels, dark sheets, dark blankets, and absorptive dressings with an impermeable backing can be used to diminish the visual impact. The environment can be managed by assuring that blood-tinged sputum is not collecting in a visible white cup at the bedside and that brilliant red-streaked blood on white tissues is kept from view.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Life-threatening hemoptysis</strong> – Patients with life-threatening hemoptysis should be immediately placed into a position in which the presumed bleeding lung is in the dependent position (eg, a patient whose right lung is bleeding should be placed in the right-side down decubitus position). The purpose of these positions is to protect the nonbleeding lung, since spillage of blood into the nonbleeding lung may prevent gas exchange by blocking the airway with clot or filling the alveoli with blood.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urgent palliative sedation</strong> – If hemoptysis is overwhelming and/or accompanied by severe hemodynamic instability and the goals of care do not support attempts at diagnosis or intervention, urgent sedation may be required. When urgent sedation is required, <a class="drug drug_general" data-topicid="9650" href="/d/drug information/9650.html" rel="external">midazolam</a> at 0.2 mg/kg administered intravenously (IV; if there is vascular access) or subcutaneously will be effective in the patient who is not chronically taking benzodiazepines  (<a class="graphic graphic_table graphicRef88423" href="/d/graphic/88423.html" rel="external">table 4</a>). This is generally administered in 5 mg increments every five minutes until sedation is achieved. A continuous infusion may be instituted to maintain sedation.</p><p></p><p class="bulletIndent1">For the patient who is tolerant to benzodiazepines, an alternative agent, such as a barbiturate, will be effective  (<a class="graphic graphic_table graphicRef88423" href="/d/graphic/88423.html" rel="external">table 4</a>). For example, <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> may be administered in a loading dose of 10 mg/kg intramuscularly (IM). Because of the relatively low concentration (it is available in 130 mg/mL vials), splitting of the total dose into two or three syringes with administration into separate IM sites may be required because of volume constraints. If sedation is not achieved, the loading dose of 10 mg/kg can be repeated every two hours to a maximum of 30 mg/kg total in the first 24 hours. If phenobarbital is administered IV, the rate should not exceed 50 mg/minute. After sedation is achieved, a continuous infusion of 10 to 25 mg/hour can be instituted. A total dose of 600 to 2400 mg/day (25 to 100 mg/hour) is often sufficient to sustain sedation [<a href="#rid62">62</a>]. (See  <a class="medical medical_review" href="/d/html/83710.html" rel="external">"Palliative sedation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Temporizing measures </strong>– In the rare instances where the underlying cause can be reversed, diagnostic tests (bronchoscopy and, if an endobronchial lesion is not identified, angiogram to identify a feeder vessel that might be amenable to bronchial artery embolization [embolotherapy] [<a href="#rid63">63</a>]) and interventional procedures may be considered, if this is consistent with the goals of care. However, for patients with life-threatening hemoptysis, this might require urgent supportive care with blood or platelet transfusion, reversal of anticoagulation, and administration of procoagulant agents.</p><p></p><p class="bulletIndent1">Radiotherapy in a single dose may stop bleeding of a malignant source if the patient is stable enough for imaging and planning. Therapeutic bronchoscopy with balloon tamponade and infusion of vasoactive agents, such as <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>, may be successful as a temporizing measure. Antifibrinolytics given orally or via nebulized routes have been used, but utility is guided mostly by anecdote and some small case reports [<a href="#rid64">64,65</a>]. One case series suggests nebulized <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> could be effective for mild to moderate hemoptysis in palliative care patients [<a href="#rid66">66</a>]. Similarly, nebulized <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> has been helpful in case reports [<a href="#rid67">67</a>]. One small trial of nebulized tranexamic acid showed significant benefit over placebo [<a href="#rid68">68</a>], and one small trial showed nebulized tranexamic acid may be more efficacious than IV tranexamic acid [<a href="#rid69">69</a>]. If the area of bleeding can be directly visualized, bronchoscopic techniques such as laser coagulation or electrocautery may also be used, with response rates of 60 to 100 percent. Insertion of a silicone stent to tamponade bleeding in lung cancer patients has been utilized as well [<a href="#rid70">70</a>]. (See  <a class="medical medical_review" href="/d/html/4394.html" rel="external">"Evaluation and management of life-threatening hemoptysis"</a>.)</p><p></p><p class="headingAnchor" id="H369324"><span class="h3">Guidelines from expert groups</span><span class="headingEndMark"> — </span>Guidelines are available for symptom management in patients with lung cancer from the American College of Chest Physicians (ACCP) [<a href="#rid41">41</a>]. For patients with hemoptysis, they recommend the following:</p><p class="bulletIndent1"><span class="glyph">●</span>For large-volume hemoptysis, the airway should be secured with a single-lumen endotracheal tube. Bronchoscopy is recommended to identify the source of bleeding, followed by endobronchial management options (eg, argon plasma coagulation, laser endobronchial resection, or electrocautery for visible central airway lesions).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For non-large-volume hemoptysis, bronchoscopy is recommended to identify the source of bleeding. For visible central airway lesions, endobronchial management options are recommended; for distal or parenchymal lesions, external beam radiotherapy is recommended.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If these measures are unsuccessful, consideration should be given to bronchial artery embolization to temporize the bleeding.</p><p></p><p class="headingAnchor" id="H698132408"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115278.html" rel="external">"Society guideline links: Subacute and chronic cough in adults"</a> and  <a class="medical medical_society_guidelines" href="/d/html/119941.html" rel="external">"Society guideline links: Palliative care for advanced lung disease"</a>.)</p><p class="headingAnchor" id="H378021384"><span class="h1">SUMMARY AND RECOMMENDATIONS</span><span class="headingEndMark"> — </span>The symptoms of cough, stridor, and hemoptysis are common in palliative care patients who have an advanced life-threatening illness, especially cancer.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cough</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In many cases, causes of and approach to cough in palliative care patients is the same as in the general population. All patients with cough should be evaluated for potentially treatable causes (eg, acute infection, exacerbation of chronic condition, medication effect), for which specific treatments may be available. (See <a class="local">'Initial evaluation'</a> above and <a class="local">'Common general causes'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Causes of cough more common in the palliative care population include swallowing abnormalities, chronic infections, and, among patients with cancer, direct or indirect effects of the tumor  (<a class="graphic graphic_table graphicRef91822" href="/d/graphic/91822.html" rel="external">table 2</a>). Directed therapies against these can help ameliorate cough. (See <a class="local">'Specific causes in palliative care'</a> above and  <a class="medical medical_review" href="/d/html/95508.html" rel="external">"Swallowing disorders and aspiration in palliative care: Assessment and strategies for management"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Symptomatic treatment of cough is appropriate when a specific cause cannot be identified or when cause-directed therapy is neither feasible nor rapidly effective. Our approach is described in the algorithm  (<a class="graphic graphic_algorithm graphicRef131668" href="/d/graphic/131668.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with mild-severity cough, we try nonpharmacologic therapies first (eg, cough suppression exercises, linctus [eg, honey]). If cough continues or worsens, we begin with a peripherally acting antitussive, such as <a class="drug drug_general" data-topicid="9098" href="/d/drug information/9098.html" rel="external">benzonatate</a>. (See <a class="local">'Mild cough'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For most patients with moderate to severe cough or for those with milder cough who do not respond to peripherally acting antitussives, we suggest a centrally acting opioid (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We typically use <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> 5 mg every four hours as needed. <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">Gabapentin</a> and <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">pregabalin</a> can be used either as alternative or concurrent treatments to opioids. (See <a class="local">'Moderate to severe cough'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stridor</strong> — Stridor is a harsh, high-pitched wheezing or vibrating sound that results from a narrowing of a central airway or the larynx caused by a foreign body, a tumor pushing extrinsically or growing intrinsically, infection, or edema. The degree of obstruction or narrowing and the rapidity of onset can precipitate a palliative care emergency. (See <a class="local">'Pathogenesis and underlying causes'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who present with stridor due to severe tracheal or mainstem bronchial obstruction or severe laryngeal edema and respiratory compromise represent a true medical emergency; they require initial stabilization to secure ventilation and oxygenation. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The dyspnea and anxiety should be managed with opioids and benzodiazepines. For highly symptomatic patients, sedation may be required to relieve distress to the satisfaction of the patient and family. (See  <a class="medical medical_review" href="/d/html/83710.html" rel="external">"Palliative sedation"</a>.)</p><p></p><p class="bulletIndent2">Once initial control of the symptom is achieved, attention to the underlying cause can be entertained. Prudent imaging, either radiographically or endoscopically, may lead to more definitive therapy (eg, palliative radiotherapy, stenting). (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemoptysis</strong> — Hemoptysis, blood coughed up from a pulmonary source, must be differentiated from pseudohemoptysis (expectoration of blood originating in the nasopharynx or oropharynx) and hematemesis. (See <a class="local">'Hemoptysis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In palliative care populations, hemoptysis can occur in patients with primary or secondary lung cancer, lung infection or abscess, bronchiectasis, pulmonary embolism, cystic fibrosis, bleeding disorders, anticoagulant use, anti-GBM (Goodpasture) disease, granulomatosis with polyangiitis, and other less common conditions  (<a class="graphic graphic_table graphicRef91871" href="/d/graphic/91871.html" rel="external">table 3</a>). (See <a class="local">'Pathogenesis and underlying causes'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The palliative treatment of hemoptysis is primarily related to managing the patient and family’s experience and efforts to stop the bleeding, if this is consistent with the overall goals of care (see <a class="local">'Management'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients with life-threatening hemoptysis should be immediately placed into a position in which the presumed bleeding lung is in the dependent position.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In the rare instances where the underlying cause of life-threatening hemoptysis can be reversed, diagnostic tests and interventional procedures may be considered, if this is consistent with the goals of care. For patients with life-threatening hemoptysis, this may require urgent supportive care with blood or platelet transfusion, reversal of anticoagulation, and/or administration of procoagulant agents. (See  <a class="medical medical_review" href="/d/html/4394.html" rel="external">"Evaluation and management of life-threatening hemoptysis"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If hemoptysis is overwhelming and/or accompanied by hemodynamic instability and the goals of care do not support attempts at diagnosis or intervention, urgent sedation may be required. (See <a class="local">'Management'</a> above and  <a class="medical medical_review" href="/d/html/83710.html" rel="external">"Palliative sedation"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Homsi J, Walsh D, Nelson KA, et al. A phase II study of hydrocodone for cough in advanced cancer. Am J Hosp Palliat Care 2002; 19:49.</a></li><li><a class="nounderline abstract_t">Hanak V, Hartman TE, Ryu JH. Cough-induced rib fractures. Mayo Clin Proc 2005; 80:879.</a></li><li><a class="nounderline abstract_t">Estfan B, LeGrand S. Management of cough in advanced cancer. J Support Oncol 2004; 2:523.</a></li><li><a class="nounderline abstract_t">Ahmedzai SH. Cough in cancer patients. Pulm Pharmacol Ther 2004; 17:415.</a></li><li><a class="nounderline abstract_t">Harle A, Molassiotis A, Buffin O, et al. A cross sectional study to determine the prevalence of cough and its impact in patients with lung cancer: a patient unmet need. BMC Cancer 2020; 20:9.</a></li><li><a class="nounderline abstract_t">Iyer S, Taylor-Stokes G, Roughley A. Symptom burden and quality of life in advanced non-small cell lung cancer patients in France and Germany. Lung Cancer 2013; 81:288.</a></li><li><a class="nounderline abstract_t">Iyer S, Roughley A, Rider A, Taylor-Stokes G. The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study. Support Care Cancer 2014; 22:181.</a></li><li><a class="nounderline abstract_t">Lin YL, Lin IC, Liou JC. Symptom patterns of patients with head and neck cancer in a palliative care unit. J Palliat Med 2011; 14:556.</a></li><li><a class="nounderline abstract_t">Scarda A, Confalonieri M, Baghiris C, et al. Out-patient high-dose-rate endobronchial brachytherapy for palliation of lung cancer: an observational study. Monaldi Arch Chest Dis 2007; 67:128.</a></li><li><a class="nounderline abstract_t">Mallick I, Sharma SC, Behera D, et al. Optimization of dose and fractionation of endobronchial brachytherapy with or without external radiation in the palliative management of non-small cell lung cancer: a prospective randomized study. J Cancer Res Ther 2006; 2:119.</a></li><li><a class="nounderline abstract_t">A Plataniotis G, Theofanopoulou MA, Sotiriadou K, et al. Palliative Hypofractionated Radiotherapy For Non-small-cell Lung Cancer (NSCLC) Patients Previously Treated By Induction Chemotherapy. J Thorac Dis 2009; 1:5.</a></li><li><a class="nounderline abstract_t">Bourke SJ, Doe SJ, Gascoigne AD, et al. An integrated model of provision of palliative care to patients with cystic fibrosis. Palliat Med 2009; 23:512.</a></li><li><a class="nounderline abstract_t">Vertigan AE, Gibson PG. The role of speech pathology in the management of patients with chronic refractory cough. Lung 2012; 190:35.</a></li><li><a class="nounderline abstract_t">Vertigan AE, Theodoros DG, Gibson PG, Winkworth AL. Efficacy of speech pathology management for chronic cough: a randomised placebo controlled trial of treatment efficacy. Thorax 2006; 61:1065.</a></li><li><a class="nounderline abstract_t">Molassiotis A, Bryan G, Caress A, et al. Pharmacological and non-pharmacological interventions for cough in adults with respiratory and non-respiratory diseases: A systematic review of the literature. Respir Med 2010; 104:934.</a></li><li><a class="nounderline abstract_t">Chamberlain S, Birring SS, Garrod R. Nonpharmacological interventions for refractory chronic cough patients: systematic review. Lung 2014; 192:75.</a></li><li><a class="nounderline abstract_t">Chamberlain S, Garrod R, Birring SS. Cough suppression therapy: does it work? Pulm Pharmacol Ther 2013; 26:524.</a></li><li><a class="nounderline abstract_t">Vertigan AE, Kapela SL, Ryan NM, et al. Pregabalin and Speech Pathology Combination Therapy for Refractory Chronic Cough: A Randomized Controlled Trial. Chest 2016; 149:639.</a></li><li><a class="nounderline abstract_t">Gibson PG, Vertigan AE. Speech pathology for chronic cough: a new approach. Pulm Pharmacol Ther 2009; 22:159.</a></li><li><a class="nounderline abstract_t">Doona M, Walsh D. Benzonatate for opioid-resistant cough in advanced cancer. Palliat Med 1998; 12:55.</a></li><li><a class="nounderline abstract_t">SIMON SW. Symptomatic treatment of asthmatic bronchitis. J Am Geriatr Soc 1960; 8:107.</a></li><li><a class="nounderline abstract_t">Schildmann EK, Rémi C, Bausewein C. Levodropropizine in the management of cough associated with cancer or nonmalignant chronic disease--a systematic review. J Pain Palliat Care Pharmacother 2011; 25:209.</a></li><li><a class="nounderline abstract_t">Mannini C, Lavorini F, Zanasi A, et al. A Randomized Clinical Trial Comparing the Effects of Antitussive Agents on Respiratory Center Output in Patients With Chronic Cough. Chest 2017; 151:1288.</a></li><li><a class="nounderline abstract_t">Aversa C, Cazzola M, Clini V, et al. Clinical trial of the efficacy and safety of moguisteine in patients with cough associated with chronic respiratory diseases. Drugs Exp Clin Res 1993; 19:273.</a></li><li><a class="nounderline abstract_t">Aliprandi P, Castelli C, Bernorio S, et al. Levocloperastine in the treatment of chronic nonproductive cough: comparative efficacy versus standard antitussive agents. Drugs Exp Clin Res 2004; 30:133.</a></li><li><a class="nounderline abstract_t">Sutherland AE, Carey M, Miller M. Fan therapy for cough: case report and literature review. BMJ Support Palliat Care 2022; 12:457.</a></li><li><a class="nounderline abstract_t">Truesdale K, Jurdi A. Nebulized lidocaine in the treatment of intractable cough. Am J Hosp Palliat Care 2013; 30:587.</a></li><li><a class="nounderline abstract_t">Slaton RM, Thomas RH, Mbathi JW. Evidence for therapeutic uses of nebulized lidocaine in the treatment of intractable cough and asthma. Ann Pharmacother 2013; 47:578.</a></li><li><a class="nounderline abstract_t">Matthys H, Bleicher B, Bleicher U. Dextromethorphan and codeine: objective assessment of antitussive activity in patients with chronic cough. J Int Med Res 1983; 11:92.</a></li><li><a class="nounderline abstract_t">Ramsay J, Wright C, Thompson R, et al. Assessment of antitussive efficacy of dextromethorphan in smoking related cough: objective vs. subjective measures. Br J Clin Pharmacol 2008; 65:737.</a></li><li><a class="nounderline abstract_t">Rühle KH, Criscuolo D, Dieterich HA, et al. Objective evaluation of dextromethorphan and glaucine as antitussive agents. Br J Clin Pharmacol 1984; 17:521.</a></li><li><a class="nounderline abstract_t">Smith HS. Opioid metabolism. Mayo Clin Proc 2009; 84:613.</a></li><li><a class="nounderline abstract_t">Yancy WS Jr, McCrory DC, Coeytaux RR, et al. Efficacy and tolerability of treatments for chronic cough: a systematic review and meta-analysis. Chest 2013; 144:1827.</a></li><li><a class="nounderline abstract_t">Molassiotis A, Bailey C, Caress A, Tan JY. Interventions for cough in cancer. Cochrane Database Syst Rev 2015; 5:CD007881.</a></li><li><a class="nounderline abstract_t">Gibson P, Wang G, McGarvey L, et al. Treatment of Unexplained Chronic Cough: CHEST Guideline and Expert Panel Report. Chest 2016; 149:27.</a></li><li><a class="nounderline abstract_t">Shi G, Shen Q, Zhang C, et al. Efficacy and Safety of Gabapentin in the Treatment of Chronic Cough: A Systematic Review. Tuberc Respir Dis (Seoul) 2018; 81:167.</a></li><li><a class="nounderline abstract_t">Dong R, Xu X, Yu L, et al. Randomised clinical trial: gabapentin vs baclofen in the treatment of suspected refractory gastro-oesophageal reflux-induced chronic cough. Aliment Pharmacol Ther 2019; 49:714.</a></li><li><a class="nounderline abstract_t">Gomes T, Greaves S, van den Brink W, et al. Pregabalin and the Risk for Opioid-Related Death: A Nested Case-Control Study. Ann Intern Med 2018; 169:732.</a></li><li><a class="nounderline abstract_t">Morice AH, McGarvey L, Pavord I, British Thoracic Society Cough Guideline Group. Recommendations for the management of cough in adults. Thorax 2006; 61 Suppl 1:i1.</a></li><li><a class="nounderline abstract_t">Morice AH, Fontana GA, Sovijarvi AR, et al. The diagnosis and management of chronic cough. Eur Respir J 2004; 24:481.</a></li><li><a class="nounderline abstract_t">Simoff MJ, Lally B, Slade MG, et al. Symptom management in patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143:e455S.</a></li><li><a class="nounderline abstract_t">Braman SS. Chronic cough due to acute bronchitis: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:95S.</a></li><li><a class="nounderline abstract_t">Bausewein C, Simon ST. Shortness of breath and cough in patients in palliative care. Dtsch Arztebl Int 2013; 110:563.</a></li><li><a class="nounderline abstract_t">Smith J, Allman D, Badri H, et al. The Neurokinin-1 Receptor Antagonist Orvepitant Is a Novel Antitussive Therapy for Chronic Refractory Cough: Results From a Phase 2 Pilot Study (VOLCANO-1). Chest 2020; 157:111.</a></li><li><a class="nounderline abstract_t">Smith JA, Kitt MM, Morice AH, et al. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial. Lancet Respir Med 2020; 8:775.</a></li><li><a class="nounderline abstract_t">Smith JA, Harle A, Dockry R, et al. Aprepitant for Cough in Lung Cancer. A Randomized Placebo-controlled Trial and Mechanistic Insights. Am J Respir Crit Care Med 2021; 203:737.</a></li><li><a class="nounderline abstract_t">Thakerar A, Simadri K, Alexander M, Fullerton S. Paroxetine for the treatment of intractable and persistent cough in patients diagnosed with cancer. J Oncol Pharm Pract 2020; 26:803.</a></li><li><a class="nounderline abstract_t">Horton MR, Santopietro V, Mathew L, et al. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med 2012; 157:398.</a></li><li><a class="nounderline abstract_t">von Gunten CF. Intractable Cough from Seizure in a Patient with Glioblastoma Multiforme. J Palliat Med 2019; 22:616.</a></li><li><a class="nounderline abstract_t">Estfan B, Walsh D. The cough from hell: diazepam for intractable cough in a patient with renal cell carcinoma. J Pain Symptom Manage 2008; 36:553.</a></li><li><a class="nounderline abstract_t">Jacome DE. La toux diabolique: neurogenic tussive crisis. Postgrad Med J 1985; 61:515.</a></li><li><a class="nounderline abstract_t">Dicpinigaitis PV, Dobkin JB. Antitussive effect of the GABA-agonist baclofen. Chest 1997; 111:996.</a></li><li><a class="nounderline abstract_t">Bastian RW, Vaidya AM, Delsupehe KG. Sensory neuropathic cough: a common and treatable cause of chronic cough. Otolaryngol Head Neck Surg 2006; 135:17.</a></li><li><a class="nounderline abstract_t">Jeyakumar A, Brickman TM, Haben M. Effectiveness of amitriptyline versus cough suppressants in the treatment of chronic cough resulting from postviral vagal neuropathy. Laryngoscope 2006; 116:2108.</a></li><li><a class="nounderline abstract_t">Lee J, Naing K, Yeo ZZ, Chong PH. The Use of Continuous Positive Airway Pressure Ventilation in the Palliative Management of Stridor in a Head and Neck Cancer Patient. J Pain Symptom Manage 2019; 58:e3.</a></li><li><a class="nounderline abstract_t">Cortelli P, Calandra-Buonaura G, Benarroch EE, et al. Stridor in multiple system atrophy: Consensus statement on diagnosis, prognosis, and treatment. Neurology 2019; 93:630.</a></li><li><a class="nounderline abstract_t">Obi J, Esquinas AM, Pastores SM. Palliative Management of Stridor in a Head and Neck Cancer Patient With Noninvasive Ventilation: Is It Safe? J Pain Symptom Manage 2019; 58:e1.</a></li><li><a class="nounderline abstract_t">Colt HG, Harrell JH. Therapeutic rigid bronchoscopy allows level of care changes in patients with acute respiratory failure from central airways obstruction. Chest 1997; 112:202.</a></li><li><a class="nounderline abstract_t">Stenekes SJ, Hughes A, Grégoire MC, et al. Frequency and self-management of pain, dyspnea, and cough in cystic fibrosis. J Pain Symptom Manage 2009; 38:837.</a></li><li><a class="nounderline abstract_t">Kvale PA, Simoff M, Prakash UB, American College of Chest Physicians. Lung cancer. Palliative care. Chest 2003; 123:284S.</a></li><li><a class="nounderline abstract_t">Miller RR, McGregor DH. Hemorrhage from carcinoma of the lung. Cancer 1980; 46:200.</a></li><li><a class="nounderline abstract_t">Stirling LC, Kurowska A, Tookman A. The use of phenobarbitone in the management of agitation and seizures at the end of life. J Pain Symptom Manage 1999; 17:363.</a></li><li><a class="nounderline abstract_t">Fujita T, Tanabe M, Moritani K, et al. Immediate and late outcomes of bronchial and systemic artery embolization for palliative treatment of patients with nonsmall-cell lung cancer having hemoptysis. Am J Hosp Palliat Care 2014; 31:602.</a></li><li><a class="nounderline abstract_t">Hankerson MJ, Raffetto B, Mallon WK, Shoenberger JM. Nebulized Tranexamic Acid as a Noninvasive Therapy for Cancer-Related Hemoptysis. J Palliat Med 2015; 18:1060.</a></li><li><a class="nounderline abstract_t">Pereira J, Phan T. Management of bleeding in patients with advanced cancer. Oncologist 2004; 9:561.</a></li><li><a class="nounderline abstract_t">Anwar D, Schaad N, Mazzocato C. Aerosolized vasopressin is a safe and effective treatment for mild to moderate recurrent hemoptysis in palliative care patients. J Pain Symptom Manage 2005; 29:427.</a></li><li><a class="nounderline abstract_t">Komura S, Rodriguez RM, Peabody CR. Hemoptysis? Try Inhaled Tranexamic Acid. J Emerg Med 2018; 54:e97.</a></li><li><a class="nounderline abstract_t">Wand O, Guber E, Guber A, et al. Inhaled Tranexamic Acid for Hemoptysis Treatment: A Randomized Controlled Trial. Chest 2018; 154:1379.</a></li><li><a class="nounderline abstract_t">Gopinath B, Mishra PR, Aggarwal P, et al. Nebulized vs IV Tranexamic Acid for Hemoptysis: A Pilot Randomized Controlled Trial. Chest 2023; 163:1176.</a></li><li><a class="nounderline abstract_t">Barisione E, Genova C, Grosso M, et al. Palliative treatment of life-threatening hemoptysis with silicone stent insertion in advanced lung cancer. Monaldi Arch Chest Dis 2017; 87:781.</a></li></ol></div><div id="topicVersionRevision">Topic 83242 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12171425" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : A phase II study of hydrocodone for cough in advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16007893" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cough-induced rib fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16302303" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Management of cough in advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15564085" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Cough in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31906892" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A cross sectional study to determine the prevalence of cough and its impact in patients with lung cancer: a patient unmet need.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23561304" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Symptom burden and quality of life in advanced non-small cell lung cancer patients in France and Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24026981" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21413849" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Symptom patterns of patients with head and neck cancer in a palliative care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18018751" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Out-patient high-dose-rate endobronchial brachytherapy for palliation of lung cancer: an observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17998689" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Optimization of dose and fractionation of endobronchial brachytherapy with or without external radiation in the palliative management of non-small cell lung cancer: a prospective randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22262995" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Palliative Hypofractionated Radiotherapy For Non-small-cell Lung Cancer (NSCLC) Patients Previously Treated By Induction Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19460834" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : An integrated model of provision of palliative care to patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21989493" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The role of speech pathology in the management of patients with chronic refractory cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16844725" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Efficacy of speech pathology management for chronic cough: a randomised placebo controlled trial of treatment efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20385478" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pharmacological and non-pharmacological interventions for cough in adults with respiratory and non-respiratory diseases: A systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24121952" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Nonpharmacological interventions for refractory chronic cough patients: systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23524013" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cough suppression therapy: does it work?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26447687" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pregabalin and Speech Pathology Combination Therapy for Refractory Chronic Cough: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19061964" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Speech pathology for chronic cough: a new approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9616460" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Benzonatate for opioid-resistant cough in advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14446944" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Symptomatic treatment of asthmatic bronchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21806417" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Levodropropizine in the management of cough associated with cancer or nonmalignant chronic disease--a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28192113" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A Randomized Clinical Trial Comparing the Effects of Antitussive Agents on Respiratory Center Output in Patients With Chronic Cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8013271" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical trial of the efficacy and safety of moguisteine in patients with cough associated with chronic respiratory diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15553659" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Levocloperastine in the treatment of chronic nonproductive cough: comparative efficacy versus standard antitussive agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32631958" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Fan therapy for cough: case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22964341" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Nebulized lidocaine in the treatment of intractable cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23548650" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Evidence for therapeutic uses of nebulized lidocaine in the treatment of intractable cough and asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6852361" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Dextromethorphan and codeine: objective assessment of antitussive activity in patients with chronic cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18279476" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Assessment of antitussive efficacy of dextromethorphan in smoking related cough: objective vs. subjective measures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6375709" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Objective evaluation of dextromethorphan and glaucine as antitussive agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19567715" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Opioid metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23928798" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Efficacy and tolerability of treatments for chronic cough: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25989380" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Interventions for cough in cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26426314" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Treatment of Unexplained Chronic Cough: CHEST Guideline and Expert Panel Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29926540" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Efficacy and Safety of Gabapentin in the Treatment of Chronic Cough: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30740748" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Randomised clinical trial: gabapentin vs baclofen in the treatment of suspected refractory gastro-oesophageal reflux-induced chronic cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30140853" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pregabalin and the Risk for Opioid-Related Death: A Nested Case-Control Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16936230" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Recommendations for the management of cough in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15358710" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The diagnosis and management of chronic cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23649452" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Symptom management in patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16428698" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Chronic cough due to acute bronchitis: ACCP evidence-based clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24069091" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Shortness of breath and cough in patients in palliative care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31421110" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The Neurokinin-1 Receptor Antagonist Orvepitant Is a Novel Antitussive Therapy for Chronic Refractory Cough: Results From a Phase 2 Pilot Study (VOLCANO-1).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32109425" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32966755" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Aprepitant for Cough in Lung Cancer. A Randomized Placebo-controlled Trial and Mechanistic Insights.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31446865" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Paroxetine for the treatment of intractable and persistent cough in patients diagnosed with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22986377" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31158050" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Intractable Cough from Seizure in a Patient with Glioblastoma Multiforme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18440768" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The cough from hell: diazepam for intractable cough in a patient with renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3925448" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : La toux diabolique: neurogenic tussive crisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9106580" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Antitussive effect of the GABA-agonist baclofen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16815176" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Sensory neuropathic cough: a common and treatable cause of chronic cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17146380" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Effectiveness of amitriptyline versus cough suppressants in the treatment of chronic cough resulting from postviral vagal neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31029806" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The Use of Continuous Positive Airway Pressure Ventilation in the Palliative Management of Stridor in a Head and Neck Cancer Patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31570638" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Stridor in multiple system atrophy: Consensus statement on diagnosis, prognosis, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31299289" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Palliative Management of Stridor in a Head and Neck Cancer Patient With Noninvasive Ventilation: Is It Safe?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9228377" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Therapeutic rigid bronchoscopy allows level of care changes in patients with acute respiratory failure from central airways obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19819666" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Frequency and self-management of pain, dyspnea, and cough in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12527586" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Lung cancer. Palliative care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6248189" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Hemorrhage from carcinoma of the lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10355215" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The use of phenobarbitone in the management of agitation and seizures at the end of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23921291" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Immediate and late outcomes of bronchial and systemic artery embolization for palliative treatment of patients with nonsmall-cell lung cancer having hemoptysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26381600" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Nebulized Tranexamic Acid as a Noninvasive Therapy for Cancer-Related Hemoptysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15477642" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Management of bleeding in patients with advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15904742" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Aerosolized vasopressin is a safe and effective treatment for mild to moderate recurrent hemoptysis in palliative care patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29502864" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Hemoptysis? Try Inhaled Tranexamic Acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30321510" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Inhaled Tranexamic Acid for Hemoptysis Treatment: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36410494" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Nebulized vs IV Tranexamic Acid for Hemoptysis: A Pilot Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28635202" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Palliative treatment of life-threatening hemoptysis with silicone stent insertion in advanced lung cancer.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
